Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mahaenggamsuk-tang (also known as Ma-Xing-Gan-Shi-Tang in Chinese medicine) is a traditional herbal formula widely used in Korea and China for the treatment of respiratory conditions, including pneumonia, bronchitis, and bronchiolitis. The formula consists of four primary herbal ingredients: *Ephedra sinica* (Ephedrae Herba), *Prunus armeniaca* (Armeniacae Semen), *Glycyrrhiza uralensis* (Glycyrrhizae Radix), and Gypsum Fibrosum. It exerts its therapeutic effects through anti-inflammatory and anti-oxidative pathways, specifically by suppressing NF-κB signaling and activating the Nrf2 pathway. It also inhibits the production of inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). Research has also explored its potential activity against viral infections, including SARS-CoV.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mahaenggamsuk-tang.